BTK and B-cell chronic lymphocytic leukemia: Novel treatments like bispecific antibodies, BTK degraders, non-covalent binding BTK inhibitors, phosphoinositide 3-kinase inhibitors, and CART may provide the solution for relapsed/refractory patients, but their sequencing order in treatment remains to be determined, especially in CLL where the treated patient population is small.